Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study

Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of HBV reactivation after R...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2018-07, Vol.13 (7), p.e0201316-e0201316
Main Authors: Jun, Baek Gyu, Kim, Young Don, Kim, Sang Gyune, Kim, Young Seok, Jeong, Soung Won, Jang, Jae Young, Lee, Sae Hwan, Kim, Hong Soo, Kang, Seong Hee, Kim, Moon Young, Baik, Soon Koo, Lee, Minjong, Kim, Tae-Suk, Choi, Dae Hee, Choi, Sang-Hyeon, Suk, Ki Tae, Kim, Dong Joon, Cheon, Gab Jin
Format: Article
Language:English
Subjects:
Activation
Analysis
Antigens
Antiviral agents
Antiviral drugs
Biology
Biology and life sciences
Cancer therapies
Chemotherapy
Combined treatment
Deoxyribonucleic acid
Diagnosis
DNA
Dosage and administration
Hepatitis
Hepatitis B
Hepatitis B surface antigen
Hepatocellular carcinoma
Hepatology
Hospitals
Interferon
Internal medicine
Liver cancer
Liver diseases
Medical records
Medicine
Medicine and health sciences
Multivariate analysis
Oncology
Patients
Physical Sciences
Physics
Radiation therapy
Radiotherapy
Research and Analysis Methods
Risk analysis
Risk factors
Treatment outcome
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of HBV reactivation after RT. Medical records of 133 HBsAg (+) HCC patients who received radiotherapy from March 2009 to February 2016 were reviewed. Patients were divided into two groups: 1) non-antiviral group, those who did not receive antiviral therapy before RT (n = 27); and antiviral group (those who underwent antiviral therapy before RT) (n = 106). Factors related to HBV reactivation in HCC patients were evaluated. 17 (12.7%) of 133 patients developed HBV reactivation after RT. Patients in the antiviral group had significantly lower rates of HBV reactivation than those in the non-antiviral group (7.5% vs. 33.3%, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0201316